# MESO catalysts: MESOBLAST LTD PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/meso/catalysts

> MESOBLAST LTD (MESO) has 6 upcoming catalysts. The next is the rexlemestrocel topline data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, year only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | MESOBLAST LTD |
| Ticker | MESO (Nasdaq) |
| SEC CIK | 1345099 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/meso |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 1, 2023 | [Remestemcel complete response letter (CRL)](https://sec-api.dev/pdufa/remestemcel) | MESO |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 08/01/2023 for BL 125706 to Mesoblast, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125706_20230801.pdf%22)) |
| Jul 2024 | [Remestemcel NDA/BLA submission](https://sec-api.dev/pdufa/remestemcel) | MESO | children with SR-aGVHD | completed | "In July 2024 we resubmitted the BLA for approval of remestemcel-L in the treatment of children with SR-aGVHD" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm)) |
| Jul 2024 | [Remestemcel NDA/BLA acceptance](https://sec-api.dev/pdufa/remestemcel) | MESO | children with steroid-refractory acute graft | completed | "July 2024 Announced the FDA accepted our Biologics License Application ("BLA") resubmission for Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease ("SR-aGVHD")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509925000090/exhibit991annualreportno.htm)) |
| July 8, 2024 | [Ryoncil (ryoncil) NDA/BLA submission](https://sec-api.dev/pdufa/ryoncil) | MESO |  | completed | "19 m e s o b l a s t Mesoblast resubmitted its Biologics License Application (BLA) to FDA for approval of RYONCIL on July 8, 2024 and anticipates a decision prior to or on the FDA's Prescription Drug User Fee Act (PDUFA) goal date of January 7, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509924000079/exhibit993-agm2024presen.htm)) |
| September 30, 2024 | [Ryoncil (ryoncil) FDA approval](https://sec-api.dev/pdufa/ryoncil) | MESO |  | completed, approved | "11 m e s o b l a s t Cash balance at September 30, 2024 is US$51.1 million, with additional US$60.0 million available from existing financing facilities on FDA approval of RYONCIL." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509924000079/exhibit993-agm2024presen.htm)) |
| December 18, 2024 | [Remestemcel FDA approval](https://sec-api.dev/pdufa/remestemcel) | MESO | children 2 months and older with SR-aGVHD | completed, approved | "Melbourne, Australia; December 19 and New York, USA; December 18, 2024: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the Food and Drug Administration (FDA) approved Ryoncil® (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the United States." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509924000087/exhibit991.htm)) |
| December 18, 2024 | [Ryoncil (ryoncil) FDA approval](https://sec-api.dev/pdufa/ryoncil) | MESO | SR-aGvHD in children 2 months and older | completed, approved | "Ryoncil® was approved by the FDA on December 18, 2024 as the first MSC therapy in the United States." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm)) |
| Jan 2025 | [Ryoncil (ryoncil) FDA approval](https://sec-api.dev/pdufa/ryoncil) | MESO | children with SR-aGVHD | completed, approved | "In January 2025, we issued 10,228,239 ordinary shares to Osiris as payment for a $20.0 million milestone following the FDA approval of Ryoncil® in the United States." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm)) |
| January 7, 2025 | [Ryoncil (ryoncil) PDUFA date](https://sec-api.dev/pdufa/ryoncil) | MESO |  | completed, approved | "19 m e s o b l a s t Mesoblast resubmitted its Biologics License Application (BLA) to FDA for approval of RYONCIL on July 8, 2024 and anticipates a decision prior to or on the FDA's Prescription Drug User Fee Act (PDUFA) goal date of January 7, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509924000079/exhibit993-agm2024presen.htm)) |
| January 7, 2025 | [Revascor (revascor) PDUFA date](https://sec-api.dev/pdufa/revascor) | MESO | congenital heart disease, adults with low ejection fraction heart failure | scheduled | "PDUFA date Jan 7th 2025 Study in adult patients for label extension to follow pediatric approval Program Key Objectives REVASCOR Heart Failure 2 3 CLBP Phase 3 trial actively enrolling at multiple sites across the U.S. The 300-patient randomized, placebo-controlled trial has a 12-month primary endpoint of pain reduction Heart failure in children with congenital heart disease, adults with low ejection fraction heart failure (HFrEF) Preparing for accelerated approval filing" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509924000079/exhibit993-agm2024presen.htm)) |
| March 28, 2025 | [Ryoncil (ryoncil) FDA approval](https://sec-api.dev/pdufa/ryoncil) | MESO | SR-aGVHD in December 2024, as well | completed, approved | "Ryoncil® is the first and only FDA approved mesenchymal stromal cell (MSC) product in the Unites States and became commercially available for purchase on March 28, 2025, within one quarter of receiving FDA approval for treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509925000058/exhibit991.htm)) |
| June 30, 2025 | [Ryoncil (ryoncil) FDA approval](https://sec-api.dev/pdufa/ryoncil) | MESO | SR-aGVHD in December 2024 | completed, approved | "Selling, marketing and distribution increased by $11.4 million from $4.7 million for the year ended June 30, 2025 to $16.1 million for the year ended June 30, 2026 primarily due to increased commercial activities for Ryoncil® following FDA approval of the product for the treatment of pediatric SR-aGVHD in December 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509926000087/exhibit991annualreportag.htm)) |
| September 30, 2025 | [MESOBLAST LTD label expansion decision](https://sec-api.dev/companies/meso/catalysts) | MESO |  | completed, approved | "RYONCIL, first & only FDA approved MSC product ✓On track for gross revenue >US$30 million this quarter ✓Onboarded >40 centers; 45 centers account for ~80% of U.S. pediatric BMTs ✓Initiating label expansion to adult aGvHD; 3-4x larger market v. pediatric ✓Inflammatory colitis trial IND filing Q1 CY26 Rexlemestrocel-L second generation platform ✓Enrollment for CLBP for expected to complete in Q1 CY26 ✓BLA filing for accelerated approval in end-stage CHF with LVADs Optimizing manufacturing & logistics in U.S. to support for future growth US$145m cash on hand at Sep 30, 2025 Management to host investor R&D day in Q1 CY26 Summary & Upcoming Milestones 22" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509925000101/exhibit992.htm)) |
| December 31, 2025 | [MESOBLAST LTD label expansion decision](https://sec-api.dev/companies/meso/catalysts) | MESO |  | completed, approved | "RYONCIL, first & only FDA approved MSC product ✓Delivered net revenue US$49 million in H1 FY26 ✓Onboarded 49 centers; 64 centers account for ~94% of U.S. pediatric BMTs ✓ Initiating label expansion to adult aGvHD; 3-4x larger market v. pediatric ✓ Prioritize portfolio including inflammatory bowel, neurodegenerative, and respiratory conditions Rexlemestrocel-L second generation platform ✓ Enrollment for CLBP for expected to complete in Mar/Apr ✓ BLA filing next quarter for full approval for RHF in end-stage HfrEF Optimizing manufacturing & logistics to support future growth US$130m cash on hand at Dec 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509926000029/exhibit992h12026results.htm)) |
| 2027 | [Rexlemestrocel topline data readout](https://sec-api.dev/pdufa/rexlemestrocel) | MESO |  | scheduled | "Most exciting is the completion of patient treatment in the Phase 3 trial of rexlemestrocel-L in the blockbuster chronic low back pain indication which will readout next year." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509926000083/exhibit991financialresul.htm)) |
| 2H 2027 | [Remestemcel topline data readout](https://sec-api.dev/pdufa/remestemcel) | MESO |  | scheduled | "A successful outcome of the CLBP Phase 3 trial readout during the second half of calendar 2027 will underpin one of the most valuable commercial opportunities in our portfolio." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509926000097/exhibit9942026agmappendi.htm)) |
| July 2027 | [Rexlemestrocel-l + ha mixture primary completion](https://sec-api.dev/pdufa/rexlemestrocel-l-ha-mixture) | MESO | Degenerative Disc Disease | scheduled | "NCT06325566 (Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Mesoblast, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06325566)) |
| Jul to Oct 2027 | [Rexlemestrocel-l + ha mixture topline data readout](https://sec-api.dev/pdufa/rexlemestrocel-l-ha-mixture) | MESO | Degenerative Disc Disease | scheduled | "NCT06325566 (Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Mesoblast, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06325566)) |
| Feb to May 2028 | [Remestemcel-l-rknd topline data readout](https://sec-api.dev/pdufa/remestemcel-l-rknd) | MESO | GVHD - Graft-Versus-Host Disease | scheduled | "NCT07568535 (A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Mesoblast, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07568535)) |
| February 2028 | [Remestemcel-l-rknd primary completion](https://sec-api.dev/pdufa/remestemcel-l-rknd) | MESO | GVHD - Graft-Versus-Host Disease | scheduled | "NCT07568535 (A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Mesoblast, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07568535)) |

## Drugs

- [Remestemcel](https://sec-api.dev/pdufa/remestemcel): children 2 months and older with sr-agvhd, sr- agvhd in pediatric patients 2 months and older, children with sr-agvhd, children with steroid-refractory acute graft
- [Remestemcel-l-rknd](https://sec-api.dev/pdufa/remestemcel-l-rknd): GVHD - Graft-Versus-Host Disease
- [Revascor (revascor)](https://sec-api.dev/pdufa/revascor): congenital heart disease, adults with low ejection fraction heart failure
- [Rexlemestrocel](https://sec-api.dev/pdufa/rexlemestrocel): 
- [Rexlemestrocel-l + ha mixture](https://sec-api.dev/pdufa/rexlemestrocel-l-ha-mixture): Degenerative Disc Disease
- [Ryoncil (ryoncil)](https://sec-api.dev/pdufa/ryoncil): children with sr-agvhd, sr-agvhd in children 2 months and older, sr-agvhd in december 2024, children with sragvhd, sr- agvhd in children 2 months and older, sr-agvhd in pediatric patients

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/meso/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MESO catalysts: MESOBLAST LTD PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/meso/catalysts

```bibtex
@misc{secapidev_companies_meso_catalysts_20261116,
  title        = {MESO catalysts: MESOBLAST LTD PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/meso/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_meso_catalysts_20261116","title":"MESO catalysts: MESOBLAST LTD PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/meso/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
